Padmanee Sharma

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
  2. doi request reprint NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 15:2130-9. 2009
  3. ncbi request reprint Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
    Derek Ng Tang
    Authors Affiliations Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Immunol Res 1:229-34. 2013
  4. pmc B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program and Ludwig Center for Cancer Immunotherapy, and Departments of Surgery and Urology, Pathology, and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19458-63. 2007
  5. ncbi request reprint Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:5442-7. 2006
  6. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
  7. ncbi request reprint Immunotherapeutic strategies for high-risk bladder cancer
    Padmanee Sharma
    Department of Genitourinary Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:165-72. 2007

Collaborators

Detail Information

Publications7

  1. ncbi request reprint Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer
    Padmanee Sharma
    Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 3:19. 2003
    ..This patient's T-cell response was determined to be specific for a new NY-ESO-1 epitope, p94-102, in the context of HLA-B35...
  2. doi request reprint NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells
    Sacha Gnjatic
    Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan Kettering Cancer Center, New York, USA
    Clin Cancer Res 15:2130-9. 2009
    ..Here, we report for the first time clinical and immune responses generated by the NY-ESO-1 DNA vaccine administered by particle-mediated epidermal delivery to cancer patients...
  3. ncbi request reprint Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy
    Derek Ng Tang
    Authors Affiliations Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer Immunol Res 1:229-34. 2013
    ....
  4. pmc B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
    Xingxing Zang
    Howard Hughes Medical Institute, Immunology Program and Ludwig Center for Cancer Immunotherapy, and Departments of Surgery and Urology, Pathology, and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19458-63. 2007
    ..Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer...
  5. ncbi request reprint Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 12:5442-7. 2006
    ..These antigens were evaluated for both the degree of expression and prognostic value in cancer of the urothelium...
  6. pmc CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
    Padmanee Sharma
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 104:3967-72. 2007
    ..001) and overall survival (P = 0.018) than did patients with similar-staged UC and fewer intratumoral CD8 TILs. We conclude that the extent of intratumoral CD8 TILs is an important prognostic indicator in advanced UC...
  7. ncbi request reprint Immunotherapeutic strategies for high-risk bladder cancer
    Padmanee Sharma
    Department of Genitourinary Medical Oncology and Immunology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:165-72. 2007
    ..In this review, we discuss the complexity of the immune system and therapies that are considered capable of manipulating it to potentially benefit patients with bladder cancer...